Development and validation of a fluorimetric method to determine curcumin in lipid and polymeric nanocapsule suspensions by Mazzarino, Letícia et al.
*Correspondence: E. L. Senna. Laboratório de Farmacotécnica, Departamento 
de Ciências Farmacêuticas, Universidade Federal de Santa Catarina, Campus 
Universitário Trindade - 88040-900 - Florianópolis - SC, Brazil. E-mail: 
lemos@ccs.ufsc.br
A
rt
ic
leBrazilian Journal of 
Pharmaceutical Sciences
vol. 46, n. 2, abr./jun., 2010
Development and validation of a fluorimetric method to determine 
curcumin in lipid and polymeric nanocapsule suspensions
Letícia Mazzarino1, Ismael Casagrande Bellettini2, Edson Minatti2, Elenara Lemos-Senna1,*
1Laboratory of Pharmaceutical Technology, Department of Pharmaceutical Sciences, Federal University of Santa Catarina, 
2Laboratory of Polymer and Surfactant Solutions, Department of Chemistry, Federal University of Santa Catarina
A simple, rapid, and sensitive fluorimetric method was developed and validated to quantify curcumin in 
lipid and polymeric nanocapsule suspensions, using acetonitrile as a solvent. The excitation and emission 
wavelengths were set at 397 nm and 508 nm, respectively. The calibration graph was linear from 0.1 
to 0.6 mg/mL with a correlation coefficient of 0.9982. The detection and quantitation limits were 0.03 
and 0.10 mg/mL, respectively. The validation results confirmed that the developed method is specific, 
linear, accurate, and precise for its intended use. The current method was successfully applied to the 
evaluation of curcumin content in lipid and polymeric nanocapsule suspensions during the early stage 
of formulation development.
Uniterms: Curcumin/determination. Fluorimetric method/quantitative analysis. Polymeric nanocapsules/
evaluation. Lipid nanocapsules/evaluation.
Um método fluorimétrico simples, rápido e sensível foi desenvolvido e validado para quantificação da 
curcumina em suspensões de nanocápsulas lipídicas e poliméricas, usando acetonitrila como solvente. 
Os comprimentos de onda de excitação e emissão foram 397 nm e 508 nm, respectivamente. Nas 
condições testadas, a curva de calibração demonstrou-se linear na faixa de 0,1 a 0,6 mg/mL, exibindo 
coeficiente de correlação de 0,9982. Os limites de detecção e quantificação foram 0,03 e 0,10 mg/mL, 
respectivamente. Os resultados da validação confirmaram que o método desenvolvido é específico, linear, 
exato e preciso para o uso proposto. O presente método foi aplicado com sucesso para a avaliação do 
teor de curcumina nas suspensões de nanocápsulas lipídicas e poliméricas durante o estágio inicial do 
desenvolvimento da formulação.
Unitermos: Curcumina/determinação. Método fluorimétrico/análise quantitativa. Nanocápsulas 
poliméricas/avaliação. Nanocápsulas lipídicas/avaliação.
INTRODUCTION
Curcumin [1,7-bis(4-hydroxy-3-methoxyphenyl)-
1,6-heptadiene-3,5-dione] (Figure 1) is a yellow polyphenol 
extracted from the rhizome of the plant Curcuma longa, 
commonly known as turmeric. It is widely used in food as 
a spice flavoring and coloring agent. The medicinal use of 
this plant has been recognized in Ayurveda for over 6000 
years (Aggarwal et al., 2003; Heath et al., 2003). Curcumin 
has been shown to possess several pharmacological actions 
including anti-inflammatory, anticancer, antioxidant and 
antimicrobial effects (Maheshwari et al., 2006). Curcumin 
has demonstrated chemopreventive properties, suppressing 
the tumorigenic activity of a wide variety of carcinogens in 
several kinds of cancer. In culture cell and animal studies, 
curcumin has been shown to exhibit antiproliferative, 
anti-invasive, and antiangiogenic properties. Curcumin has 
also demonstrated its usefulness for the treatment of other 
diseases such as diabetes, Alzheimer’s disease, Parkinson’s 
disease, and arthritis (Syng-ai et al., 2004). 
In spite of the great potential of the use of curcumin 
in therapeutics, its clinical application has been limited due 
to several drawbacks. This drug displays a poor aqueous 
solubility, preventing its administration by the intravenous 
route. When administrated orally, the majority of curcumin 
is secreted in the feces and only negligible amounts in the 
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urine, indicating that this drug is poorly absorbed from the 
gut. Pharmacokinetic studies have indicated that curcumin 
is rapidly metabolized in the liver, undergoing extensive 
reduction via alcohol dehydrogenase (Syng-ai et al., 2004). 
Besides the low systemic bioavailability expected from 
its pharmacokinetic characteristics, curcumin is quickly 
hydrolyzed at neutral and basic pH and is susceptible to pho-
tochemical degradation (Wang et al., 1997; Sharma et al., 
2001; Tonnesen et al., 2002; Tomren et al., 2007). In order 
to overcome these problems, curcumin has been associated 
with colloidal carriers. Among them, polymeric nanoparti-
cles have been considered as promising drug delivery syste-
ms due to their potential to increase the therapeutic efficacy 
and to reduce the undesirable side effects of drugs. Other 
important advantages of nanoparticles include their ability 
to carry water-insoluble drugs by intravenous route, their 
protection of active molecules against in vivo degradation, 
their ability to control drug release, ease of preparation and 
high stability in biological fluids and during storage (Gref 
et al., 1995; Fonseca et al., 2002; Gupte, Ciftci, 2004). On 
the other hand, some drawbacks of polymeric nanoparticles 
stem from the residues of organic solvents required in their 
preparation, polymer cytotoxicity, and difficulties scaling 
up the production processes. 
In recent years, the main objective of researchers 
concerning the preparation of colloidal drug carriers has 
been the development of drug delivery systems using only 
excipients acceptable for human use (Heurtault et al., 2002; 
Mehnert, Mäder, 2002). Recently, lipid nanocapsules have 
been proposed as carriers for hydrophobic drugs. Lipid 
nanocapsules are submicronic particles composed of an 
oily liquid core surrounded by a solid or semi-solid shell 
of surfactant. These systems are prepared with lipids and a 
combination of hydrophilic/lipophilic surfactants approved 
by the FDA (Heurtault et al., 2002; Dulieu, Bazile, 2005). 
Lipid nanocapsules have been prepared using the phase 
inversion process, which exploits the ability of polyetho-
xylated surfactants to change their affinities by the water 
and oil phase, as a function of the emulsion temperature, 
resulting in more stable and smaller nanoparticles. This 
method also has the advantages of being relatively simple 
and low-energy consuming, allowing easy industrial scale-
up and in particular, avoiding the use of organic solvents, 
the residues of which represent a potential risk to human 
health (Witschi, Doelker, 1997; Heurtault et al., 2003; Anton 
et al., 2008). 
The preparation of lipid and polymeric nanocapsu-
les has been explored in our research group with the aim 
of improving the stability and biological performance of 
curcumin. Firstly, we sought to evaluate the effect of the 
type of the materials (lipid or polymer) and the procedures 
employed in the preparation of the nanocapsule suspensions 
on curcumin encapsulation. As support for formulation de-
velopment as well as for future preclinical studies, a specific 
and sensitive analytical method must be developed and 
validated. The most widely used method for quantification 
of curcumin is a direct ultraviolet spectrophotometry me-
thod, but a lack of reproducibility has been observed. High 
performance liquid chromatography methods have also 
been developed to quantify curcumin, but they have the di-
sadvantages of being more time-consuming and expensive 
(Bisht et al., 2007; Nam et al., 2007; Tiyaboonchai et al., 
2007; Sou et al., 2008). Given that curcumin exhibits strong 
fluorescence in organic solvents (Díaz, Peinado, 1992), 
and the fact that no validated method has been described 
to quantify curcumin in colloidal suspensions, the develo-
pment and validation of a spectrofluorimetric method was 
undertaken to determine curcumin loading in polymeric and 
lipid nanocarrier suspensions.
MATERIAL AND METHODS
Chemicals and reagents
Curcumin and poly (D,L-lactide) (PLA, MW 90,000 
– 120,000) were purchased from Sigma-Aldrich (St. Louis, 
MO, USA). Soybean hydrogenated lecithin (LIPOID S 
75-3N) was provided by Lipoid GmbH (Ludwigshafen, 
Germany) and castor oil was obtained from Via Farma 
Importadora Ltda. (São Paulo, Brazil). Hydroxystearic 
acid-polyethylene glycol copolymer (Solutol HS 15) and 
Poloxamer (Pluronic F 68) were kindly donated by the 
BASF Chemical Company (Ludwigshafen, Germany). 
Sodium chloride was obtained from Vetec (Rio de Janeiro, 
Brazil). Except for the HPLC grade acetonitrile used in the 
analysis (Carlo Erba, Milan, Italy), all other reagents and 
solvents were analytical grade.
Preparation of the colloidal suspensions
Lipid nanocapsule suspensions
Lipid nanocapsule suspensions were prepared by 
the phase inversion method as described by Heurtault et 
al. (2002). An aqueous phase containing 8.40 g distilled 
FIGURE 1 - Chemical structure of curcumin.
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water, 0.75 g NaCl and 4.20 g Solutol HS 15 was added 
to the oil phase containing 1.40 g castor oil, 0.14 g leci-
thin, and 5 or 10 mg curcumin, both previously heated to 
90 °C, under magnetic stirring. Three temperature cycles 
alternating from 60 to 95 °C were applied to achieve the 
inversion process. During the last cooling period, the 
suspensions were rapidly diluted with 25.0 mL cold water 
(approximately 0 °C) and continuously stirred for 30 min.
Polymeric nanocapsule suspensions
Polymeric nanocapsule suspensions were prepared 
using the interfacial deposition process after solvent displa-
cement as described by Fessi et al. (1989). Briefly, 60.0 mg 
PLA, 0.250 mL castor oil, and 2.5 or 5.0 mg curcumin were 
dissolved in 2 mL of acetone. The resulting solution was 
mixed with a 10 mL acetone:ethanol (60:40, v/v) mixture 
containing 25.0 mg lecithin, and the final volume was 
adjusted to 12.0 mL. This organic phase was poured into 
an aqueous phase (26.0 mL) containing 0.375% (w/v) of 
Pluronic F 68 or Solutol HS 15, maintained under magne-
tic stirring. The organic solvents were then eliminated by 
evaporation under reduced pressure, and the final volume 
of the colloidal suspension was adjusted to 10.0 mL. 
Lipid and polymeric nanocapsule suspensions were 
filtered through filter paper with a pore size of 8 mm (J-
Prolab, São José dos Pinhais, Brazil). Unloaded lipid and 
polymeric nanocapsule suspensions were prepared and 
treated in the same manner as the samples. The nanocap-
sule suspensions were analyzed in the fluorimetric system 
after dissolution in acetonitrile.
Fluorimetric method
Steady-state fluorescence
The steady-state fluorescence spectra of curcumin 
were recorded on a Hitachi F4500 Spectrofluorimeter 
equipped with a thermostatted cell holder set at 25.0 ºC. 
The sample was continuously stirred in a standard 1 cm 
quartz cell. Both slits of excitation and emission mono-
chromators were adjusted to 5.0 nm. The samples were 
excited at 397 nm and the emission spectra were recorded 
from 440 to 600 nm. The relative fluorescence intensities 
were measured at λ
emi
 = 508 nm.
Preparation of stock and working solutions
A stock solution was prepared by accurately dissolving 
100.0 mg of curcumin in 100.0 mL of acetonitrile. From this 
solution, a working standard solution of 10.0 mg/mL was 
prepared in acetonitrile. This solution was then diluted as 
needed to prepare different standard solutions: 0.1, 0.2, 
0.3, 0.4, 0.5 and 0.6 mg/mL in acetonitrile.
Method validation
The validation parameters evaluated were speci-
ficity, linearity and range, accuracy, precision, limit of 
quantification (LOQ) and limit of detection (LOD). The 
performance characteristics were based on the pharmaceu-
tical regulatory guidelines of the International Conference 
on Harmonization (2005) and United States Pharmacopeia 
(2007).
(a) Specificity. The specificity of the fluorimetric method 
was evaluated by analyzing unloaded nanocapsule 
suspensions in order to verify whether the excipients 
used in the formulations of the nanocapsule suspen-
sions interfered in the curcumin quantification. The 
samples were analyzed in the fluorimetric system in 
triplicate.
(b) Linearity and range. Six standard solutions ranging 
from 0.1 to 0.6 mg/mL, in concentration, 3 replicates 
each, were analyzed in the fluorescence system. The 
calibration graph was obtained by plotting the fluo-
rescence intensity of the standard solutions against 
the theoretical standard concentrations. The linea-
rity was evaluated by linear least-square regression 
analysis.
(c) Accuracy. The accuracy was investigated by spiking 
unloaded nanocapsule suspensions with known con-
centrations of curcumin standard solution at 3 diffe-
rent levels (lower, medium and upper concentration) 
corresponding to curcumin final concentrations of 
0.1, 0.4 and 0.6 mg/mL. The analysis was performed 
in triplicate. The recovery (R) was estimated after 
fluorescence analysis using the following equation:
 
 where R is recovery, Csnc is the curcumin concen-
tration in the spiked nanocapsule suspension, Cnc is 
the curcumin concentration in unloaded nanocapsule 
suspension, and Css is the curcumin concentration 
in standard solution.
(d) Precision. The precision of the method was de-
termined by measuring the repeatability (intraday 
precision) and the intermediate precision (interday 
precision), both expressed as relative standard devia-
tion (RSD). The precision was evaluated by assaying 
standard solutions with different concentrations of 
curcumin (0.1, 0.2, 0.3, 0.4, 0.5 and 0.6 µg/mL). The 
repeatability was evaluated by measuring 3 samples 
of each concentration of curcumin on the same day 
under the same experimental conditions. The inter-
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mediate precision was evaluated by assaying each 
standard solution on 3 different days. The RSD was 
calculated.
(e) Limit of Quantification (LOQ). The LOQ value was 
calculated directly from the calibration graph. It is 
defined as the lowest concentration in the standard 
curve that can be measured with suitable precision 
and accuracy. LOQ may be expressed as:
 
 where d is the standard deviation (SD) of y-inter-
cepts of regression lines and S is the slope of the 
calibration graph.
(f) Limit of Detection (LOD). The LOD value was 
calculated directly from the calibration graph. It is 
defined as the lowest concentration in the standard 
curve that can be detected, but not necessarily quan-
tified as an exact value. LOD may be expressed as:
 
 where d is the standard deviation (SD) of y-inter-
cepts of regression lines and S is the slope of the 
calibration graph.
Determination of curcumin loading in 
nanocapsules
Entrapment efficiency and drug content were esti-
mated after determination of the curcumin concentration 
in the nanocapsule suspensions by fluorescence spectro-
photometry. The entrapment efficiency (%) was estimated 
as being the difference between the total concentration of 
curcumin found in the nanocapsule suspensions after their 
complete dissolution in acetonitrile and the concentration 
of drug in the supernatant obtained by the suspension 
ultrafiltration/centrifugation procedure using Microcon 
Centrifugal Filter Devices with Ultracel YM-100 mem-
brane (100 000 nominal molecular weight limit, Millipore 
Corp., USA). The drug content was expressed in mg of 
curcumin/mL of suspension.
RESULTS AND DISCUSSION
The validation of analytical procedures is proof of 
the suitability of the method for the intended purpose. The 
current guidelines define the validation characteristics 
needed for various types of test procedures, but it is the 
responsibility of the analyst to identify the critical per-
formance parameters and to design the validation study 
adequately (Ermer, 2001). Fluorimetric methods have 
shown to be sensitive, simple, rapid and reproducible 
for the quantitative determination of many compounds 
(Aktas et al., 2003; Abdellatef et al., 2006). Considering 
the biological interest of curcumin, several studies have 
previously reported the determination of this drug by fluo-
rimetric methods (Wang et al., 2006; Wang, Huang, 2007; 
Wang et al., 2008). However, the steady-state absorption 
and fluorescence characteristics of curcumin have been 
found to be sensitive to the solvent’s characteristics. Diaz 
and Peinado (1992) demonstrated that the relative fluo-
rescence intensity of curcumin increases with increasing 
solvent dielectric constant. The highest value of relative 
fluorescence intensity was obtained using acetonitrile. 
Degradation of curcumin in acetonitrile solution was also 
reported after irradiation with light (400-700 nm), but 
the live-times were long enough to perform fluorimetric 
analysis of curcumin; fluorescence readings were constant 
for at least 1 h (Khopde et al., 2000). Besides the use of 
acetonitrile to provide higher values of fluorescence inten-
sity, this solvent is able to dissolve curcumin and the lipid 
and polymeric constituents of nanocapsule suspensions, 
and for these reasons this solvent was chosen to carry out 
the analysis (Tonnesen, 2002). 
A representative emission spectrum of curcumin 
obtained under the specified fluorescence conditions is 
shown in Figure 2A. This spectrum shows an intense 
emission band in the 450 - 600 nm wavelength region, 
exhibiting a fluorescence maximum at 508 nm. In order 
to prove the specificity of the method, unloaded lipid and 
polymeric nanocapsule suspensions containing the same 
concentration of the excipients were analyzed. The fluores-
cence spectra obtained from unloaded lipid and polymeric 
nanocapsule suspensions are shown in Figures 2B, 2C 
and 2D.The spectra showed that the method was specific 
because no interference from the excipients was detected 
at 508 nm under the fluorimetric conditions employed. 
Fluorescence intensity
The calibration graph for curcumin in lipid and 
polymeric nanocapsules was linear over the range of 0.1 to 
0.6 mg/mL with a correlation coefficient of 0.9982. The re-
gression equation of the media calibration graph (n=3) was:
y = 1871x + 30.22
The slope and the intercept SDs were 50.98 and 
18.53, respectively. The validity of the assay was verified 
by analysis of variance (ANOVA), which confirmed that 
the regression equation was linear (F
calculated
 = 1557.48 > 
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F
critical 
= 3.58x10-5, P = 5%). The LOQ and LOD of the me-
thod calculated were 0.10 and 0.03 mg/mL, respectively, 
indicating that the method was sufficiently sensitive to be 
used for the drug entrapment evaluation. 
The precision of the developed method is displayed 
in Table I. The results showed that the intraday and inter-
day RSD values were lower than 5.0 % (Brasil, 2003). The 
fluorescence intensities indicated satisfactory intraday and 
interday variability.
The accuracy of the method was evaluated using 
three developed nanocapsule suspensions: lipid pre-
pared using Solutol HS15, and polymeric prepared 
using Pluronic F 68 or Solutol HS 15 as hydrophilic 
surfactants. According to the ICH, several quantitative 
approaches can be used to demonstrate the accuracy of 
the method. Spiking experiments for recovery investi-
gations should be performed mimicking authentic con-
ditions as closely as possible so that putative interferen-
ces between analyte and matrix can be observed. This 
ranges from the direct preparation of a drug product 
FIGURE 2 - Emission spectra obtained for: (A) curcumin 
standard solution, 1 mg/mL; (B,C,D) unloaded polymeric 
nanocapsule suspensions prepared using Pluronic F 68, 
unloaded polymeric nanocapsule suspensions prepared using 
Solutol HS15, and unloaded lipid nanocapsule suspensions, 
respectively.
TABLE I - Results obtained in the precision evaluation of the method
Theoretical amount 
of curcumin, mg/mL
Day No. Fluorescence intensity 
± SD
RSD, %
0.1 Intraday (n=3) 1 205.62 ± 5.25 2.55
2 197.68 ± 6.30 3.19
3 203.13 ± 1.76 0.87
Interday (n=9) 202.14 ± 4.06 2.01
0.2 Intraday (n=3) 1 420.04 ± 12.20 2.90
2 398.47 ± 11.39 2.86
3 402.64 ± 2.32 0.58
Interday (n=9) 407.05 ± 11.44 2.81
0.3 Intraday (n=3) 1 611.68 ± 23.20 3.79
2 581.73 ± 17.04 2.93
3 602.02 ± 9.13 1.52
Interday (n=9) 598.48 ± 15.28 2.55
0.4 Intraday (n=3) 1 795.88 ± 10.43 1.31
2 803.24 ± 10.18 1.27
3 790.12 ± 13.71 1.74
Interday (n=9) 796.41 ± 6.58 0.83
0.5 Intraday (n=3) 1 978.48 ± 7.07 0.72
2 988.45 ± 15.95 1.61
3 956.77 ± 20.57 2.15
Interday (n=9) 974.57 ± 16.20 1.66
0.6 Intraday (n=3) 1 1103.10 ± 4.48 0.41
2 1136.69 ± 18.26 1.61
3 1155.39 ± 29.68 2.57
Interday (n=9) 1131.73 ± 26.49 2.34
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with various contents of active ingredient to which the 
whole analytical procedure is applied, to the addition 
of a drug substance stock solution to a placebo formu-
lation (Ermer, 2001). In our case, the latter procedure 
was used in this study. The recovery was determined as 
a percentage of the difference between the experiments 
at 3 different levels. Each level was tested 3 times. The 
results given in Table II demonstrate that the method 
exhibits acceptable accuracy.
The results obtained in the evaluation of curcumin 
loading for the two kinds of nanocapsules are summarized 
in Table III. The concentration of drug in the supernatant 
obtained by the suspension ultrafiltration/centrifugation 
procedure was lower than the LOQ of the method, indica-
ting that only a very low concentration (< 0.10 mg/mL) was 
not encapsulated. Since the total concentration of curcumin 
ranged from 127.04 to 509.49 mg/mL, it is possible to state 
that for all formulations, the entrapment efficiency values 
were higher than 99%. These high values of entrapment 
efficiency obtained for curcumin could be related to the 
higher affinity of this hydrophobic drug for the oil core 
of nanocapsules. Moreover, the pH of the nanocapsule 
suspension was maintained below 6 to obtain the optimum 
stability of the preparations, preventing degradation of the 
drug. The curcumin was completely recovered in the colloi-
dal suspensions, independent of the drug amount initially 
added to the formulations. The differences of drug content 
values in the nanocapsule suspensions are related only to 
the differences in the final volume of the preparations. The 
results demonstrated that the fluorimetric method can be 
successfully applied to determine curcumin in lipid and 
polymeric nanocapsule suspensions.
CONCLUSIONS
The fluorimetric method developed and validated 
proved to be specific, linear, accurate, precise and sen-
sitive. It was successfully used to quantify curcumin in 
lipid and polymeric nanocapsule suspensions, and can be 
applied for the determination of entrapment efficiency and 
drug content, not only for formulation studies, but also 
as a pre-requisite to undertaking further chemical stabi-
lity evaluation and preclinical studies of the nanocapsule 
suspensions.
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